Scribe Therapeutics highlights data underpinning its comprehensive strategy targeting key lipid drivers of ASCVD at AHA Scientific Sessions 2025 ...

During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were ...